Loading...
•
Dec 31, 2023
Assertio Q4 2023 Earnings Report
Assertio's Q4 2023 results reflected positive indicators, including solid net product sales and positive cash flows, despite declines in Indocin and Cambia sales.
Key Takeaways
Assertio Holdings, Inc. reported Q4 net product sales of $32.5 million and cash flow from operations of $5.7 million. The company is providing guidance for 2024, targeting net product sales of $110 million to $125 million and adjusted EBITDA of $20 million to $30 million.
Net product sales were $32.5 million, a decrease from $49.9 million in the prior year fourth quarter.
Rolvedon net product sales were $11.0 million in the fourth quarter, the first full quarter following the acquisition of Spectrum.
Indocin net product sales in the fourth quarter were $10.8 million, a decrease from the prior year quarter due to declining price and volumes.
Adjusted EBITDA was $4.5 million, decreased from $33.4 million in the prior year fourth quarter, primarily due to Indocin generic competition and higher operating expenses from the acquisition of Spectrum.
Revenue by Segment
Forward Guidance
Assertio announced its initial 2024 operating guidance as follows: Net Product Sales (GAAP) $110.0 Million to $125.0 Million and Adjusted EBITDA (Non-GAAP) $20.0 Million to $30.0 Million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...